Havrix Junior

Havrix Junior is a pediatric hepatitis A vaccine that contains algeldrate and inactivated hepatitis A virus antigen. It is supplied as an injectable solution for intramuscular administration. The product is authorized in the European Union and is prescribed for active immunization against hepatitis A infection in children. Havrix Junior works by stimulating the immune system to produce protective antibodies against the hepatitis A virus safely.

Havrix Junior is indicated for the prevention of hepatitis A infection in children and for active immunization against hepatitis A virus.

- Primary prophylaxis of hepatitis A in children aged 1‑2 years. - Boosting immunity in children who have previously received a hepatitis A vaccine. - Use in outbreak settings to quickly protect susceptible pediatric populations. - Administration as part of routine childhood immunization schedules in regions where hepatitis A is endemic. - Co-administration with other pediatric vaccines when recommended by health authorities.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache or fatigue. - Nausea or mild gastrointestinal discomfort. - Mild rash or urticaria.

Serious: - Severe allergic reaction (anaphylaxis). - High fever lasting more than 48 hours. - Neurological symptoms such as seizures. - Persistent joint pain or swelling. - Guillain‑Barré syndrome (rare). - Other severe systemic reactions requiring medical attention.

Before administering Havrix Junior, healthcare providers should review the following precautions and warnings to ensure safe use.

- Confirm the child is not severely immunocompromised. - Defer vaccination in individuals with a known severe allergic reaction to any vaccine component. - Postpone if the child has an acute moderate or severe illness. - Observe the patient for at least 15 minutes after injection for immediate reactions. - Discuss pregnancy and breastfeeding status, as safety data are limited. - Ensure proper storage and handling of the vaccine according to the label.

Havrix Junior may interact with other medicines or vaccines; consider the following guidance.

Avoid: - Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) within 4 weeks.

Use with caution: - Simultaneous receipt of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) – monitor for increased local reactions. - Patients receiving immunoglobulins or blood products – may reduce vaccine efficacy. - Use in children on immunosuppressive therapy – may result in lower antibody response. - Co‑administration with antipyretics – may mask fever, but does not affect immunogenicity.